Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRD1 known ✓ | P41143 | 2/20 | 0.74 |
| ▸ | OPRM1 known ✓ | P35372 | 1/20 | 0.74 |
| ▸ | OPRK1 known ✓ | P41145 | 1/20 | 0.74 |
| ▸ | SIGMAR1 known ✓ | Q99720 | 1/20 | 0.74 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.74 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.74 |
| ▸ | CYP2C9 | P11712 | 3/20 | 0.74 |
| ▸ | HPGD | P15428 | 3/20 | 0.74 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.63 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.63 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4575803 | 0.99 | CYP1A2 (0.75) | CYP1A2CYP3A4CYP2C9HPGDOPRD1 | |
| SCHEMBL6369045 | 0.99 | CYP1A2 (0.75) | CYP1A2CYP3A4CYP2C9HPGDOPRD1 | |
| SCHEMBL6934910 | 0.99 | CYP1A2 (0.75) | CYP1A2CYP3A4CYP2C9HPGDOPRD1 | |
| SCHEMBL6557493 | 0.99 | CYP1A2 (0.75) | CYP1A2CYP3A4CYP2C9HPGDOPRD1 | |
| SCHEMBL251703 | 0.99 | CYP1A2 (0.75) | CYP1A2CYP3A4CYP2C9HPGDOPRD1 | |
| SCHEMBL4576116 | 0.99 | CYP1A2 (0.75) | CYP1A2CYP3A4CYP2C9HPGDOPRD1 | |
| SCHEMBL4576333 | 0.99 | CYP1A2 (0.75) | CYP1A2CYP3A4CYP2C9HPGDOPRD1 | |
| SCHEMBL4575415 | 0.99 | CYP1A2 (0.75) | CYP1A2CYP3A4CYP2C9HPGDOPRD1 | |
| SCHEMBL4575922 | 0.92 | OPRM1 (0.67) | CYP1A2CYP3A4CYP2C9HPGDOPRD1 | |
| SCHEMBL6935975 | 0.92 | OPRM1 (0.67) | CYP1A2CYP3A4CYP2C9HPGDOPRD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160200689-A1 | DELTA OPIOID RECEPTOR AGONIST COMPOUNDS | VERSI GROUP LLC (US) | 2016-07-14 | — | — | US | disclosed |
| US-9296707-B2 | Delta opioid receptor agonist compounds | VERSI GROUP, LLC (US) | 2016-03-29 | — | — | US | disclosed |
| US-8865721-B2 | Delta opioid receptor agonist compounds | VERSI GROUP, LLC (US) | 2014-10-21 | — | — | US | disclosed |
| US-20140031367-A1 | DELTA OPIOID RECEPTOR AGONIST COMPOUNDS | VERSI GROUP, LLC (US) | 2014-01-30 | — | — | US | disclosed |
| US-8575169-B2 | Method of treating sexual dysfunctions with delta opioid receptor agonist compounds | VERSI GROUP, LLC (US) | 2013-11-05 | — | — | US | disclosed |
| US-8551998-B2 | Delta opioid receptor agonist compounds | VERSI GROUP, LLC (US) | 2013-10-08 | — | — | US | disclosed |
| US-20130053326-A9 | Method of treating sexual dysfunctions with delta opioid receptor agonist compounds | CHANG KWEN-JEN (US) | 2013-02-28 | — | — | US | disclosed |
| EP-1469850-B1 | METHOD OF TREATING SEXUAL DYSFUNCTIONS WITH DELTA OPIOID RECEPTOR AGONIST COMPOUNDS | VERSI GROUP LLC (US) | 2013-01-02 | — | — | EP | disclosed |
| US-20120220601-A1 | DELTA OPIOID RECEPTOR AGONIST COMPOUNDS | VERSI GROUP, LLC | 2012-08-30 | — | — | US | disclosed |
| EP-1469850-A4 | METHOD OF TREATING SEXUAL DYSFUNCTIONS WITH DELTA OPIOID RECEPTOR AGONIST COMPOUNDS | ARDENT PHARMACEUTICALS INC (US) | 2008-03-12 | — | — | EP | disclosed |
| US-20070173515-A1 | DELTA OPIOID RECEPTOR AGONIST COMPOUNDS | MOUNT COOK BIOSCIENCES, INC. (US) | 2007-07-26 | — | — | US | disclosed |
| EP-1469850-A1 | METHOD OF TREATING SEXUAL DYSFUNCTIONS WITH DELTA OPIOID RECEPTOR AGONIST COMPOUNDS | Ardent Pharmaceuticals, Inc. (US) | 2004-10-27 | — | — | EP | disclosed |
| WO-2003057223-A9 | METHOD OF TREATING SEXUAL DYSFUNCTIONS WITH DELTA OPIOID RECEPTOR AGONIST COMPOUNDS | ARDENT PHARMACEUTICALS INC (US) | 2004-04-29 | — | — | WO | disclosed |
| US-20030186872-A1 | Method of treating sexual dysfunctions with delta opioid receptor agonist compounds | DMK PHARMACEUTICALS CORPORATION | 2003-10-02 | — | — | US | disclosed |
| WO-2003057223-A1 | METHOD OF TREATING SEXUAL DYSFUNCTIONS WITH DELTA OPIOID RECEPTOR AGONIST COMPOUNDS | ARDENT PHARMACEUTICALS, INC. (US) | 2003-07-17 | — | — | WO | disclosed |
| US-20020052007-A1 | Diarylmethylbenzylpiperazines and corresponding halobenzyl derivatives | ENTA HOLDING LLC | 2002-05-02 | — | — | US | disclosed |
| US-5681830-A | DIARYLMETHYL PIPERAZINE COMPOUNDS HAVING UTILITY IN MEDICAL THERAPY AS RECEPTOR-BINDING SPECIES | DELTA PHARMACEUTICALS, INC. (US) | 1997-10-28 | — | — | US | disclosed |
| US-5552404-A | COMPOUNDS FOR NEUROTRANSMITTERS FOR ANIMALS | DELTA PHARMACEUTICALS, INC. (US) | 1996-09-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160200689-A1 | DELTA OPIOID RECEPTOR AGONIST COMPOUNDS | OPRD1, OPRM1, OPRK1 | OPRD1 1/4885OPRM1 2/4885OPRK1 3/4885 |
| US-20030186872-A1 | Method of treating sexual dysfunctions with delta opioid receptor agonist compounds | OPRD1, OPRK1, OPRM1 | OPRD1 1/4885OPRM1 3/4885OPRK1 2/4885 |
| US-20070173515-A1 | DELTA OPIOID RECEPTOR AGONIST COMPOUNDS | OPRD1, OPRM1, OPRK1 | OPRD1 1/4885OPRM1 2/4885OPRK1 3/4885 |
| US-20140031367-A1 | DELTA OPIOID RECEPTOR AGONIST COMPOUNDS | OPRD1, OPRM1, OPRK1 | OPRD1 1/4885OPRM1 2/4885OPRK1 3/4885 |
| US-20120220601-A1 | DELTA OPIOID RECEPTOR AGONIST COMPOUNDS | OPRD1, OPRM1, OPRK1 | OPRD1 1/4885OPRM1 2/4885OPRK1 3/4885 |
| US-20130053326-A9 | Method of treating sexual dysfunctions with delta opioid receptor agonist compounds | OPRD1, OPRK1, OPRM1 | OPRD1 1/4885OPRM1 3/4885OPRK1 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.